Addex to Present at Biotech Showcase™ 2024

Core Insights - Addex Therapeutics is a clinical-stage pharmaceutical company focused on allosteric modulation for neurological disorders, with a pipeline that includes several promising drug candidates [2] Group 1: Corporate Update - CEO Tim Dyer will present at the Biotech Showcase in San Francisco on January 8, 2024, discussing recent advances in Addex's CNS pipeline [1] - The presentation will cover key programs including ADX71149 for epilepsy, dipraglurant for post-stroke recovery, and partnerships for substance use disorders [1][2] Group 2: Pipeline Overview - ADX71149 is currently in Phase 2 clinical trials for epilepsy in collaboration with Janssen Pharmaceuticals [2] - Dipraglurant is being evaluated for post-stroke recovery, while the GABAB PAM program has been licensed to Indivior for substance use disorder treatment [2] - The company is also advancing preclinical programs targeting chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2]